Sequana Medical to Attend 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright BIOCONNECT Virtual Conference
December 17, 2021 01:00 ET
|
Sequana Medical
GHENT, Belgium, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid...
Sequana Medical Announces Positive Interim Results of SAHARA DESERT, the alfapump DSR® Study in Heart Failure Patients with Persistent Congestion
December 07, 2021 01:00 ET
|
Sequana Medical
Interim data from six patients indicate that alfapump DSR therapy can: safely, effectively and rapidly eliminate persistent congestion and restore euvolemia in diuretic-resistant heart failure...
Sequana Medical Announces the Completion of Patient Enrolment in POSEIDON, the North American Pivotal alfapump® Study
December 06, 2021 01:00 ET
|
Sequana Medical
Positive interim analysis reported in July 2021Reporting of primary endpoint planned for Q4 2022 GHENT, Belgium, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA,...
Sequana Medical to Present at Jefferies London Healthcare Conference
November 09, 2021 01:00 ET
|
Sequana Medical
GHENT, Belgium, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease,...
Sequana Medical Receives MDSAP Certification and Expands its Quality Management System Towards North America
November 03, 2021 02:00 ET
|
Sequana Medical
GHENT, Belgium, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease,...
Sequana Medical announces H1 2021 results and provides business update
September 02, 2021 01:00 ET
|
Sequana Medical
alfapump® – Positive results from second interim analysis of POSEIDON pivotal study; awaiting FDA approval on POSEIDON pivotal study expansionalfapump® – FDA regulatory submission now expected in...
Sequana Medical Appoints Jackie Fielding, Former Medtronic VP, to its Board of Directors
August 31, 2021 01:00 ET
|
Sequana Medical
GHENT, Belgium, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease,...
Sequana Medical Notice of 2021 Half Year Results and Business Update
August 26, 2021 01:00 ET
|
Sequana Medical
GHENT, Belgium, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA, the "Company"), an innovator in the treatment of diuretic-resistant fluid overload in liver disease,...
Sequana Medical Announces Positive Results From Second Interim Analysis of North American Pivotal alfapump® Study (POSEIDON)
July 01, 2021 01:00 ET
|
Sequana Medical
Interim data from 26 patients in the Roll-In Cohort reconfirm positive outcomes against all primary endpointsi Over 90% reduction in mean frequency of therapeutic paracentesis versus baselineAll...
Sequana Medical to Host a Key Opinion Leader Webinar on “The Impact of Liver Ascites on Patients and Healthcare Systems and the potential of alfapump® therapy in NASH-related ascites”
June 17, 2021 01:00 ET
|
Sequana Medical
Live webinar with Dr. Vargas and Dr. Knuttinen on 15 July 2021 at 4 pm CET / 10 am ET GHENT, Belgium, June 17, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA, the "Company"...